Samir Nusair MD 🇮🇱
banner
samirnus.bsky.social
Samir Nusair MD 🇮🇱
@samirnus.bsky.social
Respiratory Physician, active clinician. Focused interest in #pulmonaryfibrosis #progressivePF #respiratoryphysiology #exercise #exercisetesting
What Drives #LungCancer in Nonsmokers?
This is rapidly growing clinical problem

www.medscape.com/viewarticle/...
What Drives Lung Cancer in Nonsmokers?
Lung cancer among nonsmokers is associated with germline risk factors, and EGFR/ALK-targeted therapies provide substantial benefit, a review finds.
www.medscape.com
November 12, 2025 at 2:41 AM
Sjogren disease therapy making nice progress since I reviewed pilocarpine for xerostomia in SS 25 years ago. Read "research in context" box.
www.thelancet.com/journals/lan...
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial
Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjögren's d...
www.thelancet.com
November 1, 2025 at 5:36 AM
Very interesting 👇
October 22, 2025 at 9:45 AM
Antifibrotic therapy does not alter the natural history of #pulmonaryhypertension in #pulmonaryfibrosis and other #progressivePF #fibroticILD

bmcpulmmed.biomedcentral.com/articles/10....
September 26, 2025 at 9:09 AM
Dyspnea worsening is a strong predictor of ILD progression in #Scleroserma and unlinked to changes in pulmonary function test
www.sciencedirect.com/science/arti...
The prognostic importance of worsening dyspnoea in systemic sclerosis related interstitial lung disease
To determine the prognostic importance of worsening dyspnoea in systemic sclerosis (SSc) related interstitial lung disease (ILD).SSc patients were rec…
www.sciencedirect.com
September 14, 2025 at 6:51 PM
Inhaled Recombinant human GM-CSF given 48w shows clinically significant ,around 10% rise in DLCO, with some yet not statistically significant improvement in QOL or Exercise capacity in #alveolarproteinosis #raredisease
nejm.org NEJM.org @nejm.org · Aug 20
In the IMPALA-2 phase 3 trial, the inhaled recombinant human GM-CSF molgramostim improved pulmonary gas transfer in patients with autoimmune pulmonary alveolar proteinosis. Full trial results: nej.md/476PdNU

#MedSky #PulmSky
August 26, 2025 at 8:30 AM
Our dog is inspired in her sleep, dreaming and runnig while I listen to an old lecture from the late Prof. Brian Whipp
#ExercisePhysiology #ExerciseTesting
#ERSCongress 2007
August 18, 2025 at 11:59 AM
Another therapeutic option for #pulmonaryfibrosis is coming up: Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist for IPF and PPF
journal.chestnet.org/article/S001...
Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis
These findings support further evaluation of admilparant as a therapeutic option for patients with IPF or PPF in phase 3 trials.
journal.chestnet.org
August 12, 2025 at 4:13 AM
All is good. Would reclassification help us to adjust optimal treatment and improve outcomes and clinical decisions? I sure hope so.
publications.ersnet.org/content/erj/...
Update of the International Multidisciplinary Classification of the Interstitial Pneumonias: An ERS/ATS Statement
BackgroundThe 2013 American Thoracic Society/European Respiratory Society Statement on the classification of the idiopathic interstitial pneumonias described 6 major and 2 rare subtypes of idiopathic interstitial pneumonia, as well as recognising unclassifiable disease.ObjectiveThe objective of this statement is to update the 2013 classification of interstitial pneumonia.MethodsFive co-chairs identified a committee of 32 experts in the field as well as two individuals with lived experience. Creation of the document was supported by a series of video meetings, first including the full committee and then subgroups assigned to draft specific sections of the document. The classification scheme was developed by consensus.ResultsThe multidisciplinary committee of experts identified four major advances to the classification of interstitial pneumonia: (1) expansion beyond idiopathic interstitial pneumonias to also include secondary causes; (2) identification of new subcategories and updated terms, including addition of bronchiolocentric interstitial pneumonia as a major pattern as well as changing from acute interstitial pneumonia to idiopathic diffuse alveolar damage and desquamative interstitial pneumonia to alveolar macrophage pneumonia; (3) subclassification of interstitial and alveolar filling disorders, with interstitial disorders further subclassified as fibrotic versus non-fibrotic; and (4) consideration of diagnostic confidence in patient evaluation and management. The committee also provided a comprehensive update on the status of potential molecular tools and identified future research priorities.ConclusionsThis update builds upon the previous classification approach by describing major advances in the classification of interstitial pneumonia over the last decade.
publications.ersnet.org
August 9, 2025 at 5:16 AM
Intriguing findings suggest that #Calcium Supplementation and even more together with Genetic Susceptibility may increase the incidence of Idiopathic #PulmonaryFibrosis.
A prospective cohort study.
www.sciencedirect.com/science/arti...
Calcium Supplementation, Genetic Susceptibility, and Idiopathic Pulmonary Fibrosis Risk: A Prospective Study
The association between calcium supplementation and the risk of incident idiopathic pulmonary fibrosis (IPF) is largely unknown.This study aimed to in…
www.sciencedirect.com
August 2, 2025 at 9:37 AM
On the Cover of @annalsats.bsky.social a picture of the pediatric department from which the senior author of this paper comes. The building was savagely attacked by an Iranian missile On June the 19th.
June 21, 2025 at 1:11 PM
Dupilumab and #lymphoma risk among patients with #asthma: a population-based cohort study #BiologicsAsthma
Increased incidence of T and NK cell lymphoma and CTCL.
Clinical implications, yet to be determined.
publications.ersnet.org/content/erj/...
June 21, 2025 at 9:58 AM
Rentosertib, A generative AI-discovered TNIK inhibitor for idiopathic #pulmonaryfibrosis: a randomized phase 2a trial
Interesting if consistently confirmed effective, seems to have a relatively small rate of GI side effects.
www.nature.com/articles/s41...
June 9, 2025 at 1:57 PM
Remarkable: a treatment for progressive pulm. fibrosis #fibroticILD. #Nerandomilast a molecule with #antifibrotic and anti-inflammatory effect, slows down FVC deterioration. Additionally, a weak signal of benefit on secondary end points, seen beyond week 52 of therapy.
www.nejm.org/doi/full/10....
May 21, 2025 at 2:02 PM
Methotrexate vs. PDN as 1st line therapy for pulmonary #sarcoidosis
At 24 weeks MTX was non-inferior to PDN in the effect on FVC, however as may be expected the effect of PDN was achieved earlier than MTX. Important, as MTX could be a good alternative to PDN. #ATS2025
www.nejm.org/doi/full/10....
First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate | NEJM
Prednisone is currently recommended as the first-line treatment for pulmonary sarcoidosis but is associated with many side effects. Methotrexate, which is recommended as a second-line treatment, ap...
www.nejm.org
May 19, 2025 at 12:14 PM
Should read this study carefully!
#Nerandomilast from @boehringerglobal.bsky.social an orally administered preferential inhibitor of phosphodiesterase 4B in #pulmonaryfibrosis. Results of a phase 3 study with background #antifibrotic therapy. #ATS2025
www.nejm.org/doi/full/10....
www.nejm.org
May 19, 2025 at 4:31 AM
Informative review-editorial on #bronchiectasis
nejm.org NEJM.org @nejm.org · Apr 25
Adam T. Hill, MD, describes the scientific foundations of a phase 3 study of brensocatib for the treatment of bronchiectasis.

Read the editorial “Defanging the Neutrophil to Treat Bronchiectasis”: nej.md/4cANv89

#MedSky #ScienceSky
April 26, 2025 at 11:09 AM
Phase 3 Trial of the DPP-1 Inhibitor #Brensocatib in #Bronchiectasis
Interesting that this study performed during the height of the COVID19 pandemic with probably reduced incidence of exacerbations in the placebo group, still shows a stat. significant signal of benefit.
www.nejm.org/doi/full/10....
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP...
www.nejm.org
April 26, 2025 at 7:23 AM